<DOC>
	<DOCNO>NCT00839930</DOCNO>
	<brief_summary>This study compare relative bioavailability ( rate extent absorption ) 50 mg Cilostazol Tablets manufacture TEVA Pharmaceuticals Industries Ltd. distribute TEVA Pharmaceuticals USA PLETAL Tablets manufacture Otsuka Pharmaceuticals Co. , Ltd. Otsuka America Pharmaceutical , Inc. follow single oral dose ( 1 x 50 mg tablet ) healthy adult subject administer fasting condition .</brief_summary>
	<brief_title>Cilostazol 50 mg Tablets Under Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>Screening Demographics : All volunteer select study healthy men woman 18 year age old time dose . The volunteer 's body mass index ( BMI ) less equal 30 . Screening Procedures : Each volunteer complete screening process within 28 day prior Period I dose . Consent document screen evaluation HIV antibody determination review , discuss , sign potential participant full implementation screening procedure . Screening include general observation , physical examination , demographic , medical medication history , electrocardiogram , sit blood pressure heart rate , respiratory rate temperature . The physical examination include , may limit , evaluation cardiovascular , gastrointestinal , respiratory , central nervous system . The screen clinical laboratory procedure include : Hematology : hematocrit , hemoglobin , RBC count , WBC count differential , platelet count ; Clinical Chemistry : serum creatinine , BUN , glucose , AST ( GOT ) , ALT ( GPT ) , albumin , total bilirubin , total protein , alkaline phosphatase . HIV antibody hepatitis B surface antigen hepatitis C antibody screen ; Urinalysis : dipstick ; full microscopic examination dipstick positive ; Urine Drug Screen : ethyl alcohol , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine metabolite , opiate , phencyclidine ; Serum Pregnancy Screen ( female volunteer ) . Follicle Stimulating Hormone ( FSH ; female subject ) : verify postmenopausal status If female : postmenopausal least 1 year postmenopausal status define : &gt; 60 year age amenorrheic least one year ; 60 year age young , must also serum FSH level &gt; 30 IU/L ; surgically sterile least 6 month ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) . Volunteers recent history drug alcohol addiction abuse . Volunteers presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined clinical investigator ) . Volunteers whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant . Volunteers demonstrate positive hepatitis B surface antigen screen reactive HIV antibody screen . Volunteers demonstrate positive drug abuse screen screen study . Female volunteer demonstrate positive pregnancy screen . Female volunteer currently breastfeed . Volunteers history allergic response ( ) cilostazol relate drug . Volunteers history clinically significant allergy include drug allergy . Volunteers clinically significant illness 4 week prior Period I dose ( determined clinical investigator ) . Volunteers currently use report use tobacco product within 90 day prior Period I dose . Volunteers take drug know induce inhibit hepatic drug metabolism 30 day prior Period I dose . Volunteers report donate great 150 mL blood within 30 day prior Period I dose . All subject advise donate blood four week complete study . Volunteers donate plasma ( e.g . plasmapheresis ) within 14 day prior Period I dose . All subject advise donate plasma four week complete study . Volunteers report receive investigational drug within 30 day prior Period I dose . Volunteers report take prescription medication nonprescription medication 14 day 7 day , respectively , prior Period I dose exception topical product without systemic absorption . Volunteers abnormal diet 28 day prior Period I dose . Volunteers report intolerance direct venipuncture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>